Skip to main content
Top
Published in: Addiction Science & Clinical Practice 1/2019

Open Access 01-12-2019 | Naloxone | Review

Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders

Authors: Paxton Bach, Daniel Hartung

Published in: Addiction Science & Clinical Practice | Issue 1/2019

Login to get access

Abstract

The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US.
Literature
1.
go back to reference Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. Hyattsville: National Center for Health Statistics; 2018. Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. Hyattsville: National Center for Health Statistics; 2018.
2.
3.
go back to reference SUPPORT for Patients and Communities Act, Pub. L. No. 115-271; 2018. SUPPORT for Patients and Communities Act, Pub. L. No. 115-271; 2018.
4.
go back to reference Nguyen DQ, Chung B, Osburn LL, Della Paolera MA, Chavez B. Utilization of pharmacists in addressing medication abuse in the Pacific Northwest. J Pharm Pract. 2016;30(5):528–33.PubMedCrossRef Nguyen DQ, Chung B, Osburn LL, Della Paolera MA, Chavez B. Utilization of pharmacists in addressing medication abuse in the Pacific Northwest. J Pharm Pract. 2016;30(5):528–33.PubMedCrossRef
5.
go back to reference Van Hout MC, Norman I. Misuse of non-prescription codeine containing products: recommendations for detection and reduction of risk in community pharmacies. Int J Drug Policy. 2016;27:17–22.PubMedCrossRef Van Hout MC, Norman I. Misuse of non-prescription codeine containing products: recommendations for detection and reduction of risk in community pharmacies. Int J Drug Policy. 2016;27:17–22.PubMedCrossRef
7.
go back to reference Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631–5.PubMedPubMedCentral Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631–5.PubMedPubMedCentral
8.
go back to reference Aitken M, Kleinrock M. Medicine use and spending in the U.S. A review of 2018 and outlook to 2023. IQVIA Institute for Human Data Science; 2019. Aitken M, Kleinrock M. Medicine use and spending in the U.S. A review of 2018 and outlook to 2023. IQVIA Institute for Human Data Science; 2019.
9.
go back to reference Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, et al. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues. 2011;41(2):283–304.PubMedPubMedCentralCrossRef Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, et al. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues. 2011;41(2):283–304.PubMedPubMedCentralCrossRef
10.
go back to reference Drug Enforcement Administration. Pharmacist’s manual: an informational outline of the Controlled Substances Act. Springfield: United States Department of Justice, Drug Enforcement Administration, Office of Diversion Control; 2010. Drug Enforcement Administration. Pharmacist’s manual: an informational outline of the Controlled Substances Act. Springfield: United States Department of Justice, Drug Enforcement Administration, Office of Diversion Control; 2010.
11.
go back to reference Cochran G, Field C, Lawson K, Erickson C. Pharmacists’ knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. J Pharm Health Serv Res. 2013;4(2):71–9.CrossRef Cochran G, Field C, Lawson K, Erickson C. Pharmacists’ knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. J Pharm Health Serv Res. 2013;4(2):71–9.CrossRef
12.
go back to reference Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2015;28(4):404–12.PubMedCrossRef Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2015;28(4):404–12.PubMedCrossRef
13.
go back to reference Dhital R, Norman I, Whittlesea C, Murrells T, McCambridge J. The effectiveness of brief alcohol interventions delivered by community pharmacists: randomized controlled trial. Addiction. 2015;110(10):1586–94.PubMedPubMedCentralCrossRef Dhital R, Norman I, Whittlesea C, Murrells T, McCambridge J. The effectiveness of brief alcohol interventions delivered by community pharmacists: randomized controlled trial. Addiction. 2015;110(10):1586–94.PubMedPubMedCentralCrossRef
14.
go back to reference Dhital R, Whittlesea CM, Milligan P, Khan NS, Norman IJ. The impact of training and delivering alcohol brief intervention on the knowledge and attitudes of community pharmacists: a before and after study. Drug Alcohol Rev. 2013;32(2):147–56.PubMedCrossRef Dhital R, Whittlesea CM, Milligan P, Khan NS, Norman IJ. The impact of training and delivering alcohol brief intervention on the knowledge and attitudes of community pharmacists: a before and after study. Drug Alcohol Rev. 2013;32(2):147–56.PubMedCrossRef
15.
go back to reference Khan NS, Norman IJ, Dhital R, McCrone P, Milligan P, Whittlesea CM. Alcohol brief intervention in community pharmacies: a feasibility study of outcomes and customer experiences. Int J Clin Pharm. 2013;35(6):1178–87.PubMedCrossRef Khan NS, Norman IJ, Dhital R, McCrone P, Milligan P, Whittlesea CM. Alcohol brief intervention in community pharmacies: a feasibility study of outcomes and customer experiences. Int J Clin Pharm. 2013;35(6):1178–87.PubMedCrossRef
16.
go back to reference Winstanley EL, Mashni R, Schnee S, Miller N, Mashni SM. The development and feasibility of a pharmacy-delivered opioid intervention in the emergency department. J Am Pharm Assoc. 2017;57(2s):S87–91.CrossRef Winstanley EL, Mashni R, Schnee S, Miller N, Mashni SM. The development and feasibility of a pharmacy-delivered opioid intervention in the emergency department. J Am Pharm Assoc. 2017;57(2s):S87–91.CrossRef
17.
go back to reference Cochran G, Field C, Karp J, Seybert AL, Chen Q, Ringwald W, et al. A community pharmacy intervention for opioid medication misuse: a pilot randomized clinical trial. J Am Pharm Assoc. 2018;58(4):395–403.CrossRef Cochran G, Field C, Karp J, Seybert AL, Chen Q, Ringwald W, et al. A community pharmacy intervention for opioid medication misuse: a pilot randomized clinical trial. J Am Pharm Assoc. 2018;58(4):395–403.CrossRef
18.
go back to reference Nielsen S, Kowalski M, Wood P, Larney S, Bruno R, Shanahan M, et al. Routine opioid outcome monitoring in community pharmacy: pilot implementation study protocol. Res Soc Adm Pharm. 2018;15(8):1047–55.CrossRef Nielsen S, Kowalski M, Wood P, Larney S, Bruno R, Shanahan M, et al. Routine opioid outcome monitoring in community pharmacy: pilot implementation study protocol. Res Soc Adm Pharm. 2018;15(8):1047–55.CrossRef
19.
go back to reference Pringle JL, Cochran J, Aruru M. Role of pharmacists in the opioid use disorder (OUD) crisis. Res Soc Adm Pharm. 2018;15(2):228–9.CrossRef Pringle JL, Cochran J, Aruru M. Role of pharmacists in the opioid use disorder (OUD) crisis. Res Soc Adm Pharm. 2018;15(2):228–9.CrossRef
21.
go back to reference Strand MA, Eukel H, Burck S. Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk. Res Soc Adm Pharm. 2019;15(8):1032–6.CrossRef Strand MA, Eukel H, Burck S. Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk. Res Soc Adm Pharm. 2019;15(8):1032–6.CrossRef
22.
go back to reference Rickles NM, Huang AL, Gunther MB, Chan WJ. An opioid dispensing and misuse prevention algorithm for community pharmacy practice. Res Soc Adm Pharm. 2019;15(8):959–65.CrossRef Rickles NM, Huang AL, Gunther MB, Chan WJ. An opioid dispensing and misuse prevention algorithm for community pharmacy practice. Res Soc Adm Pharm. 2019;15(8):959–65.CrossRef
23.
go back to reference Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013;48(9):761–8.PubMedCrossRef Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013;48(9):761–8.PubMedCrossRef
24.
go back to reference Hartung DM, Hall J, Haverly SN, Cameron D, Alley L, Hildebran C, et al. Pharmacists’ role in opioid safety: a focus group investigation. Pain Med. 2017;19(9):1799–806.CrossRefPubMedCentral Hartung DM, Hall J, Haverly SN, Cameron D, Alley L, Hildebran C, et al. Pharmacists’ role in opioid safety: a focus group investigation. Pain Med. 2017;19(9):1799–806.CrossRefPubMedCentral
25.
go back to reference Fleming ML, Barner JC, Brown CM, Shepherd MD, Strassels SA, Novak S. Pharmacists’ training, perceived roles, and actions associated with dispensing controlled substance prescriptions. J Am Pharm Assoc. 2014;54(3):241–50.CrossRef Fleming ML, Barner JC, Brown CM, Shepherd MD, Strassels SA, Novak S. Pharmacists’ training, perceived roles, and actions associated with dispensing controlled substance prescriptions. J Am Pharm Assoc. 2014;54(3):241–50.CrossRef
26.
go back to reference Freeman PR, Curran GM, Drummond KL, Martin BC, Teeter BS, Bradley K, et al. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: results from a multi-site qualitative study. Res Soc Adm Pharm. 2018;15(6):754–60.CrossRef Freeman PR, Curran GM, Drummond KL, Martin BC, Teeter BS, Bradley K, et al. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: results from a multi-site qualitative study. Res Soc Adm Pharm. 2018;15(6):754–60.CrossRef
27.
go back to reference Johnston K, Alley L, Novak K, Haverly S, Irwin A, Hartung D. Pharmacists’ attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: a brief scoping review. J Am Pharm Assoc. 2018;58(5):568–76.CrossRef Johnston K, Alley L, Novak K, Haverly S, Irwin A, Hartung D. Pharmacists’ attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: a brief scoping review. J Am Pharm Assoc. 2018;58(5):568–76.CrossRef
28.
go back to reference Schepis TS, McCabe SE, Teter CJ. Sources of opioid medication for misuse in older adults: results from a nationally representative survey. Pain. 2018;159(8):1543–9.PubMedPubMedCentralCrossRef Schepis TS, McCabe SE, Teter CJ. Sources of opioid medication for misuse in older adults: results from a nationally representative survey. Pain. 2018;159(8):1543–9.PubMedPubMedCentralCrossRef
29.
go back to reference Kennedy-Hendricks A, Gielen A, McDonald E, McGinty EE, Shields W, Barry CL. Medication sharing, storage, and disposal practices for opioid medications among US adults. JAMA Intern Med. 2016;176(7):1027–9.PubMedCrossRef Kennedy-Hendricks A, Gielen A, McDonald E, McGinty EE, Shields W, Barry CL. Medication sharing, storage, and disposal practices for opioid medications among US adults. JAMA Intern Med. 2016;176(7):1027–9.PubMedCrossRef
31.
go back to reference Balick R. Washington is first state with funded statewide drug take-back program. Pharm Today. 2018;24(6):47.CrossRef Balick R. Washington is first state with funded statewide drug take-back program. Pharm Today. 2018;24(6):47.CrossRef
32.
go back to reference Strategy to combat opioid abuse, misuse, and overdose. US Department of Health and Human Services; 2018. Strategy to combat opioid abuse, misuse, and overdose. US Department of Health and Human Services; 2018.
33.
go back to reference Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract. 2017;12(1):4.PubMedPubMedCentralCrossRef Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract. 2017;12(1):4.PubMedPubMedCentralCrossRef
34.
go back to reference Preventing the consequences of opioid overdose: understanding naloxone access laws. SAMHSA’s Center for the Application of Prevention Technologies; January 20, 2018. Accessed 23 July 2018. Preventing the consequences of opioid overdose: understanding naloxone access laws. SAMHSA’s Center for the Application of Prevention Technologies; January 20, 2018. Accessed 23 July 2018.
36.
go back to reference Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018;189:37–41.PubMedCrossRef Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018;189:37–41.PubMedCrossRef
37.
go back to reference Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019;179(6):805–11.PubMedCrossRefPubMedCentral Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019;179(6):805–11.PubMedCrossRefPubMedCentral
38.
go back to reference McClellan C, Lambdin BH, Ali MM, Mutter R, Davis CS, Wheeler E, et al. Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018;86:90–5.PubMedCrossRef McClellan C, Lambdin BH, Ali MM, Mutter R, Davis CS, Wheeler E, et al. Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018;86:90–5.PubMedCrossRef
39.
go back to reference Puzantian T, Gasper JJ. Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation. JAMA. 2018;320(18):1933–4.PubMedPubMedCentralCrossRef Puzantian T, Gasper JJ. Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation. JAMA. 2018;320(18):1933–4.PubMedPubMedCentralCrossRef
40.
go back to reference Guadamuz JS, Alexander GC, Chaudhri T, Trotzky-Sirr R, Qato DM. Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017. JAMA Netw Open. 2019;2(6):e195388.PubMedPubMedCentralCrossRef Guadamuz JS, Alexander GC, Chaudhri T, Trotzky-Sirr R, Qato DM. Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017. JAMA Netw Open. 2019;2(6):e195388.PubMedPubMedCentralCrossRef
41.
go back to reference Meyerson BE, Agley JD, Davis A, Jayawardene W, Hoss A, Shannon DJ, et al. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016. Drug Alcohol Depend. 2018;188:187–92.PubMedPubMedCentralCrossRef Meyerson BE, Agley JD, Davis A, Jayawardene W, Hoss A, Shannon DJ, et al. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016. Drug Alcohol Depend. 2018;188:187–92.PubMedPubMedCentralCrossRef
42.
go back to reference Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J. 2015;12:25.PubMedPubMedCentralCrossRef Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J. 2015;12:25.PubMedPubMedCentralCrossRef
43.
go back to reference Hawk M, Coulter RWS, Egan JE, Fisk S, Reuel Friedman M, Tula M, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14(1):70.PubMedPubMedCentralCrossRef Hawk M, Coulter RWS, Egan JE, Fisk S, Reuel Friedman M, Tula M, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14(1):70.PubMedPubMedCentralCrossRef
44.
go back to reference Wiessing L, Ferri M, Belackova V, Carrieri P, Friedman SR, Folch C, et al. Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J. 2017;14(1):19.PubMedPubMedCentralCrossRef Wiessing L, Ferri M, Belackova V, Carrieri P, Friedman SR, Folch C, et al. Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J. 2017;14(1):19.PubMedPubMedCentralCrossRef
45.
go back to reference Gaddis A, Kennedy MC, Nosova E, Milloy MJ, Hayashi K, Wood E, et al. Use of on-site detoxification services co-located with a supervised injection facility. J Subst Abuse Treat. 2017;82:1–6.PubMedPubMedCentralCrossRef Gaddis A, Kennedy MC, Nosova E, Milloy MJ, Hayashi K, Wood E, et al. Use of on-site detoxification services co-located with a supervised injection facility. J Subst Abuse Treat. 2017;82:1–6.PubMedPubMedCentralCrossRef
47.
go back to reference Janulis P. Pharmacy nonprescription syringe distribution and HIV/AIDS: a review. J Am Pharm Assoc. 2012;52(6):787–97.CrossRef Janulis P. Pharmacy nonprescription syringe distribution and HIV/AIDS: a review. J Am Pharm Assoc. 2012;52(6):787–97.CrossRef
48.
go back to reference Davidson PJ, Martinez A, Lutnick A, Kral AH, Bluthenthal RN. Drug-related deaths and the sales of needles through pharmacies. Drug Alcohol Depend. 2015;147:229–34.PubMedCrossRef Davidson PJ, Martinez A, Lutnick A, Kral AH, Bluthenthal RN. Drug-related deaths and the sales of needles through pharmacies. Drug Alcohol Depend. 2015;147:229–34.PubMedCrossRef
49.
go back to reference Stopka TJ, Geraghty EM, Azari R, Gold EB, DeRiemer K. Is crime associated with over-the-counter pharmacy syringe sales? Findings from Los Angeles, California. Int J Drug Policy. 2014;25(2):244–50.PubMedCrossRef Stopka TJ, Geraghty EM, Azari R, Gold EB, DeRiemer K. Is crime associated with over-the-counter pharmacy syringe sales? Findings from Los Angeles, California. Int J Drug Policy. 2014;25(2):244–50.PubMedCrossRef
51.
go back to reference Zaller N, Jeronimo A, Bratberg J, Case P, Rich JD. Pharmacist and pharmacy staff experiences with non-prescription (NP) sale of syringes and attitudes toward providing HIV prevention services for injection drug users (IDUs) in Providence, RI. J Urban Health. 2010;87(6):942–53.PubMedPubMedCentralCrossRef Zaller N, Jeronimo A, Bratberg J, Case P, Rich JD. Pharmacist and pharmacy staff experiences with non-prescription (NP) sale of syringes and attitudes toward providing HIV prevention services for injection drug users (IDUs) in Providence, RI. J Urban Health. 2010;87(6):942–53.PubMedPubMedCentralCrossRef
52.
go back to reference Fernandes RM, Cary M, Duarte G, Jesus G, Alarcao J, Torre C, et al. Effectiveness of needle and syringe programmes in people who inject drugs—an overview of systematic reviews. BMC Public Health. 2017;17(1):309.PubMedPubMedCentralCrossRef Fernandes RM, Cary M, Duarte G, Jesus G, Alarcao J, Torre C, et al. Effectiveness of needle and syringe programmes in people who inject drugs—an overview of systematic reviews. BMC Public Health. 2017;17(1):309.PubMedPubMedCentralCrossRef
53.
go back to reference Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a cochrane review and meta-analysis. Addiction. 2018;113(3):545–63.PubMedCrossRef Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a cochrane review and meta-analysis. Addiction. 2018;113(3):545–63.PubMedCrossRef
54.
go back to reference Sawangjit R, Khan TM, Chaiyakunapruk N. Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis. Addiction. 2017;112(2):236–47.PubMedCrossRef Sawangjit R, Khan TM, Chaiyakunapruk N. Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis. Addiction. 2017;112(2):236–47.PubMedCrossRef
55.
go back to reference Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68.PubMedCrossRef Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68.PubMedCrossRef
56.
go back to reference Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59–66.PubMedCrossRef Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59–66.PubMedCrossRef
57.
go back to reference Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, Rich JD, et al. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct J. 2018;15(1):7.PubMedPubMedCentralCrossRef Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, Rich JD, et al. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct J. 2018;15(1):7.PubMedPubMedCentralCrossRef
58.
go back to reference Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2018;63:122–8.PubMedCrossRef Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2018;63:122–8.PubMedCrossRef
59.
go back to reference Strike C, Hopkins S, Watson TM, Gohil H, Leece P, Young S, et al. Best practice recommendations for Canadian harm reduction programs that provide service to people who use drugs and are at risk for HIV, HCV, and other harms: Part 1. Toronto: Working Group on Best Practice for Harm Reduction Programs in Canada; 2013. Strike C, Hopkins S, Watson TM, Gohil H, Leece P, Young S, et al. Best practice recommendations for Canadian harm reduction programs that provide service to people who use drugs and are at risk for HIV, HCV, and other harms: Part 1. Toronto: Working Group on Best Practice for Harm Reduction Programs in Canada; 2013.
61.
go back to reference Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789.PubMedPubMedCentralCrossRef Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789.PubMedPubMedCentralCrossRef
62.
go back to reference Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003–2015 (update). The CBHSQ Report, Rockville; 2017. p. 1–8. Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003–2015 (update). The CBHSQ Report, Rockville; 2017. p. 1–8.
63.
go back to reference Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108–12.PubMedCrossRef Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108–12.PubMedCrossRef
64.
go back to reference Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–6.PubMedPubMedCentralCrossRef Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–6.PubMedPubMedCentralCrossRef
65.
go back to reference Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–8.PubMedPubMedCentralCrossRef Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–8.PubMedPubMedCentralCrossRef
66.
go back to reference Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.PubMedCrossRef Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.PubMedCrossRef
67.
go back to reference Goldstein A. Heroin addiction and the role of methadone in its treatment. Arch Gen Psychiatry. 1972;26(4):291–7.PubMedCrossRef Goldstein A. Heroin addiction and the role of methadone in its treatment. Arch Gen Psychiatry. 1972;26(4):291–7.PubMedCrossRef
68.
go back to reference Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
69.
go back to reference Rettig RA, Yarmolinsky A. Federal regulation of methadone treatment. Washington, DC: National Academies Press; 1995. Rettig RA, Yarmolinsky A. Federal regulation of methadone treatment. Washington, DC: National Academies Press; 1995.
70.
go back to reference Lenardson J, Gale J. Distribution of substance abuse treatment facilities across the rural–urban continuum. Portland: University of Southern Maine; 2007. Lenardson J, Gale J. Distribution of substance abuse treatment facilities across the rural–urban continuum. Portland: University of Southern Maine; 2007.
71.
go back to reference Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas—United States. CDC Surveill Summ. 2017;66(19):1–12.CrossRef Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas—United States. CDC Surveill Summ. 2017;66(19):1–12.CrossRef
72.
go back to reference Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–63.PubMedPubMedCentralCrossRef Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–63.PubMedPubMedCentralCrossRef
73.
go back to reference Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007–2015. PLoS ONE. 2017;12(8):e0183172.PubMedPubMedCentralCrossRef Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007–2015. PLoS ONE. 2017;12(8):e0183172.PubMedPubMedCentralCrossRef
74.
go back to reference European Monitoring Centre for Drugs and Drug Addiction. Cost and financing of drug treatment services in Europe: an exploratory study. Lisboa: European Monitoring Centre for Drugs and Drug Addiction; 2011. European Monitoring Centre for Drugs and Drug Addiction. Cost and financing of drug treatment services in Europe: an exploratory study. Lisboa: European Monitoring Centre for Drugs and Drug Addiction; 2011.
75.
go back to reference Moore TJ, Ritter A, Caulkins JP. The costs and consequences of three policy options for reducing heroin dependency. Drug Alcohol Rev. 2007;26(4):369–78.PubMedCrossRef Moore TJ, Ritter A, Caulkins JP. The costs and consequences of three policy options for reducing heroin dependency. Drug Alcohol Rev. 2007;26(4):369–78.PubMedCrossRef
76.
go back to reference Zaric GS, Brennan AW, Varenbut M, Daiter JM. The cost of providing methadone maintenance treatment in Ontario, Canada. Am J Drug Alcohol Abuse. 2012;38(6):559–66.PubMedPubMedCentralCrossRef Zaric GS, Brennan AW, Varenbut M, Daiter JM. The cost of providing methadone maintenance treatment in Ontario, Canada. Am J Drug Alcohol Abuse. 2012;38(6):559–66.PubMedPubMedCentralCrossRef
77.
go back to reference Roebuck MC, French MT, McLellan AT. DATStats: results from 85 studies using the drug abuse treatment cost analysis program. J Subst Abuse Treat. 2003;25(1):51–7.PubMedCrossRef Roebuck MC, French MT, McLellan AT. DATStats: results from 85 studies using the drug abuse treatment cost analysis program. J Subst Abuse Treat. 2003;25(1):51–7.PubMedCrossRef
78.
go back to reference Gauthier G, Eibl JK, Marsh DC. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies. Drug Alcohol Depend. 2018;191:1–5.PubMedCrossRef Gauthier G, Eibl JK, Marsh DC. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies. Drug Alcohol Depend. 2018;191:1–5.PubMedCrossRef
79.
go back to reference Chaar BB, Wang H, Day CA, Hanrahan JR, Winstock AR, Fois R. Factors influencing pharmacy services in opioid substitution treatment. Drug Alcohol Rev. 2013;32(4):426–34.PubMedCrossRef Chaar BB, Wang H, Day CA, Hanrahan JR, Winstock AR, Fois R. Factors influencing pharmacy services in opioid substitution treatment. Drug Alcohol Rev. 2013;32(4):426–34.PubMedCrossRef
80.
go back to reference Lawrinson P, Roche A, Terao H, Le PP. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. Drug Alcohol Rev. 2008;27(1):47–53.PubMedCrossRef Lawrinson P, Roche A, Terao H, Le PP. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. Drug Alcohol Rev. 2008;27(1):47–53.PubMedCrossRef
81.
go back to reference Sheridan J, Manning V, Ridge G, Mayet S, Strang J. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995–2005. Addiction. 2007;102(11):1824–30.PubMedCrossRef Sheridan J, Manning V, Ridge G, Mayet S, Strang J. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995–2005. Addiction. 2007;102(11):1824–30.PubMedCrossRef
82.
go back to reference Matheson C, Bond CM, Tinelli M. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health (Oxf). 2007;29(4):350–7.CrossRef Matheson C, Bond CM, Tinelli M. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health (Oxf). 2007;29(4):350–7.CrossRef
83.
go back to reference Winstock AR, Lea T, Sheridan J. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. Addiction. 2010;105(2):335–42.PubMedCrossRef Winstock AR, Lea T, Sheridan J. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. Addiction. 2010;105(2):335–42.PubMedCrossRef
84.
go back to reference Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug Alcohol Rev. 2007;26(2):143–51.PubMedCrossRef Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug Alcohol Rev. 2007;26(2):143–51.PubMedCrossRef
85.
go back to reference Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician. 2011;57(3):281–9.PubMedPubMedCentral Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician. 2011;57(3):281–9.PubMedPubMedCentral
86.
go back to reference Lea T, Sheridan J, Winstock A. Consumer satisfaction with opioid treatment services at community pharmacies in Australia. Pharm World Sci. 2008;30(6):940–6.PubMedCrossRef Lea T, Sheridan J, Winstock A. Consumer satisfaction with opioid treatment services at community pharmacies in Australia. Pharm World Sci. 2008;30(6):940–6.PubMedCrossRef
87.
go back to reference Lutnick A, Case P, Kral AH. Injection drug users’ perspectives on placing HIV prevention and other clinical services in pharmacy settings. J Urban Health. 2012;89(2):354–64.PubMedPubMedCentralCrossRef Lutnick A, Case P, Kral AH. Injection drug users’ perspectives on placing HIV prevention and other clinical services in pharmacy settings. J Urban Health. 2012;89(2):354–64.PubMedPubMedCentralCrossRef
88.
go back to reference Gidman W, Coomber R. Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the West of Scotland. Res Soc Adm Pharm. 2014;10(3):576–87.CrossRef Gidman W, Coomber R. Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the West of Scotland. Res Soc Adm Pharm. 2014;10(3):576–87.CrossRef
89.
go back to reference Matheson C, Jaffray M, Ryan M, Bond CM, Fraser K, Kirk M, et al. Public opinion of drug treatment policy: exploring the public’s attitudes, knowledge, experience and willingness to pay for drug treatment strategies. Int J Drug Policy. 2014;25(3):407–15.PubMedCrossRef Matheson C, Jaffray M, Ryan M, Bond CM, Fraser K, Kirk M, et al. Public opinion of drug treatment policy: exploring the public’s attitudes, knowledge, experience and willingness to pay for drug treatment strategies. Int J Drug Policy. 2014;25(3):407–15.PubMedCrossRef
90.
go back to reference Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188–209.PubMedPubMedCentralCrossRef Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188–209.PubMedPubMedCentralCrossRef
91.
go back to reference Alanis-Hirsch K, Croff R, Ford JH 2nd, Johnson K, Chalk M, Schmidt L, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. J Subst Abuse Treat. 2016;62:68–73.PubMedCrossRef Alanis-Hirsch K, Croff R, Ford JH 2nd, Johnson K, Chalk M, Schmidt L, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. J Subst Abuse Treat. 2016;62:68–73.PubMedCrossRef
92.
go back to reference Oji V, McKoy-Beach Y, Pagan T, Matike B, Akiyode O. Injectable administration privileges among pharmacists in the United States. Am J Health Syst Pharm. 2012;69(22):2002–5.PubMedCrossRef Oji V, McKoy-Beach Y, Pagan T, Matike B, Akiyode O. Injectable administration privileges among pharmacists in the United States. Am J Health Syst Pharm. 2012;69(22):2002–5.PubMedCrossRef
93.
go back to reference Bonner L. Kentucky pharmacists operate novel long-acting injection clinic. Pharm Today. 2017;23(8):6.CrossRef Bonner L. Kentucky pharmacists operate novel long-acting injection clinic. Pharm Today. 2017;23(8):6.CrossRef
94.
go back to reference Skelton J, Rothholz M, Vatanka P. Report of the APhA stakeholder conference on improving patient access to injectable medications. J Am Pharm Assoc. 2017;57:e1–12.CrossRef Skelton J, Rothholz M, Vatanka P. Report of the APhA stakeholder conference on improving patient access to injectable medications. J Am Pharm Assoc. 2017;57:e1–12.CrossRef
95.
go back to reference Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol. 2011;71(6):832–43.PubMedPubMedCentralCrossRef Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol. 2011;71(6):832–43.PubMedPubMedCentralCrossRef
96.
go back to reference Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.PubMedPubMedCentralCrossRef Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.PubMedPubMedCentralCrossRef
97.
go back to reference A guideline for the clinical management of opioid use disorder. Vancouver: British Columbia Centre on Substance Use; 2017. A guideline for the clinical management of opioid use disorder. Vancouver: British Columbia Centre on Substance Use; 2017.
98.
go back to reference Guidance for injectable opioid agonist treatment for opioid use disorder. Vancouver: British Columbia Centre on Substance Use; 2018. Guidance for injectable opioid agonist treatment for opioid use disorder. Vancouver: British Columbia Centre on Substance Use; 2018.
99.
go back to reference Hartung DM, Hall J, Haverly SN, Cameron D, Alley L, Hildebran C, et al. Pharmacists’ Role in opioid safety: a focus group investigation. Pain Med. 2018;19(9):1799–806.PubMedCrossRef Hartung DM, Hall J, Haverly SN, Cameron D, Alley L, Hildebran C, et al. Pharmacists’ Role in opioid safety: a focus group investigation. Pain Med. 2018;19(9):1799–806.PubMedCrossRef
Metadata
Title
Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
Authors
Paxton Bach
Daniel Hartung
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Addiction Science & Clinical Practice / Issue 1/2019
Electronic ISSN: 1940-0640
DOI
https://doi.org/10.1186/s13722-019-0158-0

Other articles of this Issue 1/2019

Addiction Science & Clinical Practice 1/2019 Go to the issue